BRAF: Difference between revisions
(Created page with "BRAF is a gene that encodes a protein called B-Raf, which is part of the MAPK/ERK signaling pathway involved in regulating cell growth and division. Mutations in the BRAF gene, particularly the V600E mutation, are commonly found in various cancers, including melanoma, colorectal, and thyroid cancers. These mutations lead to the continuous activation of the B-Raf protein, driving uncontrolled cell proliferation and tumor growth. Detecting BRAF mutations in cancer patients...") |
No edit summary |
||
| Line 1: | Line 1: | ||
BRAF is a gene that encodes a protein called B-Raf, which is part of the MAPK/ERK signaling pathway involved in regulating cell growth and division. Mutations in the BRAF gene, particularly the V600E mutation, are commonly found in various cancers, including melanoma, colorectal, and thyroid cancers. These mutations lead to the continuous activation of the B-Raf protein, driving uncontrolled cell proliferation and | BRAF is a gene that encodes a protein called B-Raf, which is part of the MAPK/ERK signaling pathway involved in regulating cell growth and division. Mutations in the BRAF gene, particularly the V600E mutation, are commonly found in various cancers, including melanoma, colorectal, and thyroid cancers. These mutations lead to the continuous activation of the B-Raf protein, driving uncontrolled cell proliferation and tumour growth. Detecting BRAF mutations in cancer patients is critical for guiding targeted therapy decisions, as specific inhibitors can effectively block the aberrant B-Raf activity. Understanding BRAF mutations allows for personalized treatment approaches, improving the effectiveness of therapies and offering better outcomes for patients with BRAF-mutant cancers. | ||
Latest revision as of 14:23, 27 August 2024
BRAF is a gene that encodes a protein called B-Raf, which is part of the MAPK/ERK signaling pathway involved in regulating cell growth and division. Mutations in the BRAF gene, particularly the V600E mutation, are commonly found in various cancers, including melanoma, colorectal, and thyroid cancers. These mutations lead to the continuous activation of the B-Raf protein, driving uncontrolled cell proliferation and tumour growth. Detecting BRAF mutations in cancer patients is critical for guiding targeted therapy decisions, as specific inhibitors can effectively block the aberrant B-Raf activity. Understanding BRAF mutations allows for personalized treatment approaches, improving the effectiveness of therapies and offering better outcomes for patients with BRAF-mutant cancers.
